K-1000 Chewable Specification

Name: K-1000 Chewable Tablets (1 Box = 30 Tablets)
Brand: Taabib.com
Price: 809.0 PKR
Availability: InStock

Requires Prescription (YES/NO)

Generics

Calcium , Vitamin D , Vitamin K2

Used For

Bones & Joints Care

How it works

It is a combination product containing Calcium, Vitamin D3 (Cholecalciferol) and Vitamin K2 (menaquinone-7) that helps strengthen bones and aids in the treatment/prevention of osteoporosis, osteomalacia, hypo-parathyroidism and other bone disorders or to overcome deficiencies of calcium and Vitamin D3 in certain populations and disease states. It is also used to improve and maintain bone mineral density (BMD), bone health and strength .

K-1000 Chewable Usage And Safety

Dosage

Calcium , Vitamin D , Vitamin K2

Side Effects

Common: Constipation or stomach upset may occur. Uncommon: Hypercalcemia/hypercalciuria, Nausea/vomiting, loss of appetite, unusual weight loss, mental/mood changes, change in the amount of urine, bone/muscle pain, headache, increased thirst, increased urination, weakness, tiredness, fast/pounding heartbeat. Rare: Serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing .

Drug Interactions

Calcium can decrease the absorption of other drugs such as tetracycline antibiotics (e.g., doxycycline, minocycline), bisphosphonates (e.g., alendronate), estramustine, levothyroxine, and quinolone antibiotics (e.g., ciprofloxacin, levofloxacin). There should be a gap of at least 4 hours when taking these drugs with K-1000. Certain medications can decrease the absorption of Vitamin D3 (bile acid sequestrants such as cholestyramine/colestipol, mineral oil, orlistat). There should be a gap of at least 4 hours when taking these drugs with K-1000. Patients co-treated with cardiac glycosides along with cholecalciferol may be susceptible to high calcium levels and should have ECG parameters and calcium levels monitored. It is recommended to reduce the dose or interrupt treatment if the calcium content in the urine exceeds 7.5 mmol/24 hours (300 mg/24 hours). Simultaneous administration of benzothiadiazine derivatives (thiazide diuretics increases the risk of hypercalcaemia because they decrease the calcium excretion in the urine. The calcium levels in plasma and urine should therefore be monitored for patients undergoing long-term treatment with calcium/Vitamin D3 supplementation.

Indication

K-1000 chewable tablets are used to prevent conditions related to calcium and Vitamin D3 deficiency such as: a) Osteoporosis b) Osteomalacia c) Hypoparathyroidism d) Musculoskeletal pain . K-1000 chewable tablets are also used to overcome calcium and Vitamin D3 deficiencies in certain populations and disease states such as:a) Postmenopausal women b) Bone recovery after fractures . K-1000 chewable tablets may also be used to prevent or treat bone-related disorders such as osteoporosis in people taking certain medication.

When not to Use

K-1000 must not be used in patients with: Hypersensitivity to any of the active substances (Vitamin D3 or its analogues, calcium or Vitamin K2 or its analogues). Due to calcium / cholecalciferol components, K-1000 tablets must not be used in: Hypercalcaemia and/or hypercalciuria Nephrolithiasis (Renal calculi) Hypervitaminosis D Severe renal impairment Metastatic calcification .

K-1000 Chewable Precautions

Precaution

Renal diseases (Kidney disease). Cholecalciferol should be used with caution in patients with impairment of renal function due to the potential exacerbation of hypercalcemic effects during therapeutic use. The effect on calcium and phosphate levels should also be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, Vitamin D3 in the form of cholecalciferol is not metabolized normally and other forms of Vitamin D3 should be used .

K-1000 Chewable Warnings

Warning 1

Certain immune system disorder (Sarcoidosis). Cholecalciferol should be prescribed with caution to patients suffering from sarcoidosis because of the risk of increased metabolism of Vitamin D3 to its active form. These patients should be monitored with regard to the calcium content in serum and urine.

Warning 2

Liver disease. In patients with liver impairment, Vitamin D3 absorption may be markedly impaired; conversion to active metabolite calcifediol may be reduced significantly, with the requirement of high doses of cholecalciferol. Agents not requiring hepatic hydroxylation are preferred in this condition. It is not reasonable to use cholecalciferol in severe liver impairment .

Warning 3

Untreated phosphate imbalance. There is a risk of metastatic calcification; normalization of phosphate levels is indicated prior to therapy with cholecaciferol. Do not exceed the recommended dose.

K-1000 Chewable Tablets (1 Box = 30 Tablets)